“Government Negotiation” of Drug Prices
Developed binding arbitration scenarios that could be implemented as part of a future “government negotiation” policy reform for prescription drugs.
Developed binding arbitration scenarios that could be implemented as part of a future “government negotiation” policy reform for prescription drugs. Analyzed past and current use of binding arbitration in the health care and non-health care settings, with a specific focus on the prescription drug model adopted by Germany. Provided mi
CEO insights
Related articles
Real analysis from people who’ve been there
Evaluation of Biosimilar Utilization by Hospital Types
Worked with a pharmaceutical trade organization to identify biosimilars of interest.
Advocacy Coalition for Uptake of Comprehensive Genomic Profiling
Worked with a diverse group of industry stakeholders including diagnostics manufacturers, laboratories, academic institutions, and disease-specific advocacy groups to redefine comprehensive genomic profiling through the creation of a “new narrative”.
Reach out
Own your edge
We don’t just guide the market. We shape it. Map your market access moves with #ADVIIntelligence. Proven advantage. Unmatched partnership.